Accordingly, the primary objective of the present study was to develop a breast cancer mouse model that is cyclically administered cyclophosphamide (a potent standalone antitumour agent) and simultaneously provided an ovarian protective agent, rapamycin (an mTOR inhibitor known for its antitumour properties). Here, MTOR is linked to breast cancer.